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Abstract
Purpose: Signal transducer and activator of transcription 3 (STAT3) has shown to play a critical role in head and neck
squamous cell carcinoma (HNSCC) and we have recently completed clinical trials of STAT3 decoy oligonucleotide in patients
with recurrent or metastatic HNSCC. However, there is limited understanding of the role of STAT3 in modulating other
aspects of tumorigenesis such as angiogenesis. In this study, we aimed to examine the effects of STAT3 decoy
oligonucleotide on tumor angiogenesis.
Experimental Design: A STAT3 decoy oligonucleotide and small interfering RNA (siRNA) were used to inhibit STAT3 in
endothelial cells in vitro and in vivo. The biochemical effects of STAT3 inhibition were examined in conjunction with the
consequences on proliferation, migration, apoptotic staining, and tubule formation. Additionally, we assessed the effects of
STAT3 inhibition on tumor angiogenesis using murine xenograft models.
Results: STAT3 decoy oligonucleotide decreased proliferation, induces apoptosis, decreased migration, and decreased
tubule formation of endothelial cells in vitro. The STAT3 decoy oligonucleotide also inhibited tumor angiogenesis in murine
tumor xenografts. Lastly, our data suggest that the antiangiogenic effects of STAT3 decoy oligonucleotide were
mediatedthrough the inhibition of both STAT3 and STAT1.
Conclusions: The STAT3 decoy oligonucleotidewas found to be an effective antiangiogenic agent, which is likely to
contribute to the overall antitumor effects of this agent in solid tumors.Taken together with the previously demonstrated
antitumor activity of this agent, STAT3 decoy oligonucleotide represents a promising single agent approach to targeting
both the tumor and vascular compartments in various malignancies.
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Introduction
Signal transducer and activator of transcription 3 (STAT3) has
been proven to be critical in tumor cell growth, viability, and
metastasis in head and neck cancer among other cancer types [1].
STAT3 is activated downstream of both the EGFR and IL6
signaling pathways. Both EGFR expression and IL6 production
are poor prognostic indicators for many cancers and therapeutic
agents that target these pathways are either established treatments
or are under investigation for many malignancies including
HNSCC [2,3]. Due to the involvement of STAT3 in key
regulatory pathways in tumor cells, several investigators have
examined the efficacy of inhibiting STAT3 as anti-cancer therapy.
One promising approach that has been used to inhibit STAT3 is
the decoy oligonucleotide strategy. The STAT3 decoy oligonu-
cleotide is a 15-mer double stranded oligonucleotide that mimics
the STAT3 binding region on the endogenous DNA, acting
primarily by competing with the endogenous DNA for binding of
activated STAT3 dimers. The STAT3 decoy oligonucleotide has
been studied as anti-tumor agent in several types of cancer such as
ovarian, breast, hepatocellular, and lung cancer as well as
malignant glioma [4–8]. We have shown previously that the
STAT3 decoy oligonucleotide is able to inhibit the growth of
HNSCC cell lines and xenografts in nude mice [9–12]. Based
primarily on our promising preclinical data, we have recently
completed a phase 0, biomarker driven clinical trial of STAT3
decoy oligonucleotide in patients with resectable HNSCC [13].
The results of this study was recently published and demonstrated
that STAT3 decoy oligonucleotide is able to efficiently downreg-
ulate STAT3 regulated genes in human tumors.
Given the promise of the STAT3 decoy oligonucleotide as a
therapeutic approach in HNSCC, we aimed to fully understand
the mechanisms by which the STAT3 decoy oligonucleotide exerts
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its antitumor effects. It is well established that STAT3 is activated
in endothelial cells by various cytokines such as IL-6 and vascular
endothelial growth factor (VEGF) [14–16]. STAT3 is believed to
play a critical role in the physiology of endothelial cells including
responses to oxidative stress and inflammation [17,18]. Therefore,
we hypothesized thatSTAT3 decoy oligonucleotide is an efficient
inhibitor of tumor angiogenesis. By utilizing in vitro assays as well as
scaffold-based in vivo angiogenesis assay, we show that the STAT3
decoy oligonucleotide has potent, direct antiangiogenic properties.
These results underscore the utility of STAT3 decoy oligonucle-
otide as a single agent that targets both the tumor cell and
endothelial cell compartment and provide further rationale for the
development of STAT3 inhibitors for treatment of solid malig-
nancies.
Materials and Methods
Cell lines
Human umbilical vein endothelial cells (HUVEC) and human
dermal microvascular endothelial cells (HDMEC) were our
endothelial cell models (Lonza, Walkersville, MD). These endo-
thelial cells were grown in microvascular endothelial cell growth
medium-2 (Lonza, Walkersville, MD). T24 cell line was main-
tained in DMEM (Mediatech, Manassas, V) and 10% FBS
(Bioexpress, Kaysville, UT).
Reagents
The STAT3 decoy oligonucleotide sequence was 59-
CATTTCCCGTAAATC-39, 39GTAAAGGGCATTTAC-59
and the STAT3 mutant control oligonucleotide was 59-
CATTTCCCTTAAATC-39, 39-GTAAAGGGAATTTAG-5
and the first and last three bases in each strand were
phosphorothioated (IDT, San Diego, CA). We also used a sense
strand that was tagged at the 5-end with Fluorescein amidite
(FAM). The decoy oligonucleotide was annealed prior to use by
boiling for 5 minutes and made to 100 mM stock. The STAT3
decoy oligonucleotide used in vivo (NSC-741763) is the identical
sequence, but double stranded (NCI, Biopharmaceutical Devel-
opment Program, Frederick, MD) [12]. The human pooled
STAT1 (L-003543-00) and STAT3 (M-003544-02) specific siRNA
was used to downregulate STAT1 and STAT3 in vitro (Dharmacon
Products, Lafayette, CO). The following antibodies were used for
immunohistochemical analysis: rat monoclonal anti-CD31/plate-
let/endothelial cell adhesion molecule 1 (CD31/PECAM-1)
(PharMingen, SanDiego, CA); peroxidase-conjugated goat anti-
rat immunoglobulin G1 (Jackson Research Laboratories, West
Grove, PA) and Alexa Fluor 594–conjugated goat anti-rat
immunoglobulin G (Invitrogen, Carlsbad, CA).
Cell viability assay
HUVECs or HDMECs were plated at 36104 cells per well in a
24 well plate and grown in complete EGM-2 media. After
24 hours the cells were transfected with the STAT3 decoy
oligonucleotide (0 nM–10000 nM) and a mutant control oligonu-
cleotide (10000 nM) using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) in optimum growth medium (Invitrogen, Carlsbad,
CA). Following transfection the cells were placed in complete
EGM-2. 72 hours post treatment the cells were assessed for
viability using Thiazolyl Blue Tetrazolium Bromide (MTT)
(Sigma, St. Louis, MO).
Apoptosis assay
16106 HUVECs were plated on 10 cm dishes and grown in
complete EGM-2. After 24 hours the cells were transfected with
the STAT3 decoy oligonucleotide (0 nM–100 nM) or mutant
control oligonucleotide (100 nM), or treated with cisplatin as
positive control. After 24 hours the cells were trypsinized, washed,
and resuspended in 16 binding buffer (BioVision, San Francisco,
CA). FITC-conjugated Annexin-V reagent (BioVision, San
Francisco, CA) was added to the cells and the cells were analyzed
with a FACScalibur (BD Biosciences, San Diego, CA) to quantify
the number of cells positive for FITC. The data was represented as
the percentage of cells positive for Annexin-V detection.
In vitro tubule formation assay
HUVECs were transfected with either the STAT3 decoy
oligonucleotide (100 nM) or the STAT3 mutant control oligonu-
cleotide (100 nM) using lipofectamine 2000 in optimum growth
medium. 24 hours post transfection, 56103 treated HUVECs
were plated in a 96 well plate on top of growth factor reduced
Matrigel (BD Biosciences, San Diego, CA). After 24 hours the
wells were imaged using 46 phase contrast microscopy and the
images were quantified for tubule formation.
Live cell imaging
56105 HUVECs were plated in a 10 cm dish and transfected
with either the STAT3 mutant control oligonucleotide or the
FAM-tagged STAT3 decoy oligonucleotide. Twenty four hours
after transfection, 56104 HUVECs were plated on top of Matrigel
in a 0.17 mm clear Delta T Dish (BioptechsInc, Butler, PA). The
cells were placed in 37uC for 15 minutes to allow adherence and
were subsequently imaged on a Nikon Ti inverted microscope with
perfect focus using phase contrast at 106. Images were captured
every 10 minutes for 24 hours in 8 unique fields with a Roper
Scientific Cascade 1K camera using MetaMorph 7.73 software.
Cell tracking was performed with the track objects application in
Metamorph to obtain mean distance traveled, mean velocity and
distance from origin.
Transwell migration assay
HUVECs were transfected with either the STAT3 decoy
(100 nM) or the STAT3 mutant control (100 nM) using
lipofectamine 2000 in optimum growth medium. 24 hours post
transfection, 16103 treated HUVECs were plated in a hydrated
8.0 micron control insert (BD Biosciences, San Diego, CA) with
serum free EBM-2 (Lonza, Walkersville, MD) and placed in a 24-
well companion plate containing complete EGM-2. After 24 hours
the inserts were fixed and stained using the Protocol Hema 3 Stain
Set (Fisher Scientific Company, Kalamazoo, MI). The cell number
in each insert was counted and recorded as number of cells
migrated.
Xenograft formation and treatment
All animal studies were performed with approval by the
Institutional Animal Care and Use Committee at the University
of Pittsburgh (approval number 0909400). 26106UM-22B
HNSCC cells were injected subcutaneouslyinto flanksof nude
mice. Once palpable tumors were achieved, treatment was
initiated with the STAT3 decoy oligonucleotide (50 mg/50 ml),
the STAT3 mutant control oligonucleotide (50 mg/50 ml), or the
vehicle control (50 ml PBS) via intratumoral injection. The tumors
were treated for three weeks. At the end of the treatment period,
the mice were sacrificed. The tumor xenografts were harvested
and frozen at 280uC.
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Immunohistochemical-Immunofluorescent Analysis
Frozen tissues were used for detection of CD31/PECAM-1, and
terminal deoxynucleotidyltransferase-mediated dUTP nick end
labeling (TUNEL). Slides were prepared as previously described
[19]. Immunostaining for CD31/PECAM-1 (1:400) were per-
formed using the methods indicated as previously described [19].
TUNEL assay was performed using DeadEndFluorometric
TUNEL System (Promega, Madison, WI). For CD31-TUNEL
double staining, TUNEL staining was performed on slides already
labeled with anti-CD31 antibody, as described above. Endothelial
cells were identified by red fluorescent staining, and DNA
fragmentation was detected by localized green and yellow
fluorescence within the nuclei of apoptotic cells.
Quantification of Microvessel Density, Apoptotic Tumor
and Endothelial Cells
For quantification of TUNEL expression, the cells positively
stained were counted in 15 0.04-mm2 fields with a 206
objective.Vessels completely stained with anti-CD31 antibodies
were counted in random 0.04-mm2 fields at using a 206objective.
Quantification of apoptotic endothelial cells (CD31/TUNEL) was
measured as the average of the ratio of apoptotic endothelial cells
to the total number of endothelial cells in 10 random 0.01-mm2
fields at using a 406 objective.
In vivo angiogenesis assay using PLLA scaffolds
Poly-L-lactic acid (PLLA) scaffolds were prepared as previously
described and cut into 6 mm66 mm61 mm sections [20,21].
16106 HUVECs per sponge were resuspended 1:1 with media
and Matrigel (BD Biosciences, San Diego, CA). Each scaffold was
seeded with the 16106 endothelial cells and incubated at 37uC for
30 minutes and then placed on ice. The sponges were implanted 2
per mouse on both flanks via subcutaneous implantation as
previously described [20,21]. After 3 days in the mice, the mice
were treated via per-scaffold injections of either the clinical grade
STAT3 decoy oligonucleotide (50 mg/50 ml) or the STAT3
mutant control oligonucleotide (50 mg/50 ml) for 15 days. At the
end of the treatment period, the scaffolds were excised, formalin
fixed and paraffin embedded.
Western blotting
40 mg of protein was resolved in an 8% SDS-PAGE gel and
transferred onto a Nitrocellulose membrane using a semidry
transfer machine (Bio-Rad Laboratories, Hercules, CA). Western
blot was then performed with the appropriate primary and
secondary antibodies. The blot was developed with luminol
reagent (Santa Cruz Biotechnology, Santa Cruz, CA). The band
intensity was quantitated with DigiDoc1000 software (Alpha
Innatech Corporation, San Leandro, CA).
Statistical analysis
The quantifications were compared with the paired Student’st-
test. Statistical analyses were performed with Prism 5.01 software
(GraphPad Software). P values,0.05 were considered statistically
significant.
Results
STAT3 decoy oligonucleotide decreases cell viability and
induces apoptosis of human endothelial cells
We first assessed the in vitro effects of the STAT3 decoy
oligonucleotide on endothelial cells by examining the effects of
STAT3 decoy on the viability of HUVEC and HDMEC (Fig. 1A
& B). Compared with the mutant control oligonucleotide, STAT3
decoy oligonucleotide treatment induced a dose-dependent
decrease in the viability of HUVEC and HDMEC. The effective
IC50 of STAT3 decoy treatment for HUVEC and HDMEC were
8 nM and 137 nM, respectively. Both the HUVEC and HDMEC
demonstrated greater sensitivity to the STAT3 decoy oligonucle-
otide than any of HNSCC cell lines tested in previously published
studies, highlighting the importance of STAT3 in endothelial cell
physiology and angiogenesis [9]. While both HUVEC and
HDMEC were sensitive to the STAT3 decoy oligonucleotide,
HUVEC was used as the primary model for the subsequent
experiments as its sensitivity to the STAT3 decoy was higher than
HDMEC.
It is well known that some of the STAT3 target genes include
genes such as Bcl-xl which is involved in antiapoptosis [22].
Therefore, we next examined the effects of STAT3 decoy
oligonucleotide on the apoptosis of HUVEC. HUVECs were
treated with increasing concentrations of STAT3 decoy oligonu-
cleotide and the degree of apoptosis was examined using a flow
cytometric apoptosis assay. Compared to the mutant control
oligonucleotide, STAT3 decoy oligonucleotide produced a dose-
dependent induction of apoptosis in HUVEC (Fig. 1C). Lastly, we
examined the effects of STAT3 oligonucleotide on the migration
of HUVEC using trans-well migration assay. In this assay, STAT3
decoy oligonucleotide decreased the migration of endothelial cells
when compared to the STAT3 mutant control oligonucleotide
(p,0.05) (Fig. 1D).
STAT3 decoy inhibits HUVEC tubule formation
We next examine the in vitro effect of the STAT3 decoy
oligonucleotide on the angiogenic potential of HUVECs using
tubule formation assay. HUVECs were treated with either the
STAT3 decoy oligonucleotide or the mutant control oligonucle-
otide and then plated on Matrigel. Compared with the mutant
control oligonucleotide, STAT3 decoy oligonucleotide produced a
significant decrease in tubule formation (Fig. 2A). The degree of
tubule formation was quantified by assessing the number of
tubules and the number of nodes (intersection point of at least two
tubules). Both tubule node and tubule number were significantly
decreased with STAT3 decoy oligonucleotide treatment compared
with the mutant control oligonucleotide (p,0.05)(Fig. 2B & C).
In order to further characterize the effects of STAT3 decoy
oligonucleotide on the process of tubule formation, we performed
a live-cell assay in which the process of tubule formation was
examined with serial photography. HUVECs treated with the
STAT3 decoy oligonucleotide or mutant control oligonucleotides
were plated on Matrigel and images were taken every 10 minutes
for 24 hours in 8 unique fields of each treatment. The STAT3
decoy oligonucleotides were FAM-tagged to confirm successful
transfection (Fig. 3A). Using computer-assisted analysis, all
HUVECs that remained in the field the duration of the
experiment were tracked (Fig. 3B). This novel live assay allowed
us to assess specific movement parameters during the process of
tubule formation including mean distanced traveled, mean
velocity and mean distance from origin (Fig. 3C–E). Despite the
decrease in tubule formation with STAT3 decoy oligonucleotide
treatment, there were no statistically significant differences in the
mean distance traveled and the mean velocity between the mutant
control and STAT3 decoy oligonucleotide treated HUVECs.
However, there was a statistically significant decrease in the mean
distance traveled from the point of origin in HUVECs treated with
STAT3 decoy oligonucleotide compared with HUVECs treated
with STAT3 mutant control oligonucleotide (p,0.05). Although
this data is preliminary, it suggests that the inhibition of tubule
Antiangiogenic STAT3 Decoy Oligonucleotide
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formation by STAT3 decoy oligonucleotide may occur by
interference with the chemotactic rather than the migratory
aspect of tubule formation.
STAT3 decoy oligonucleotide inhibits tubule formation in
vitro via inhibition of both STAT1 and STAT3
While the STAT3 decoy oligonucleotide is effective at
abrogating STAT3-mediated gene transcription, previous work
from our lab demonstrated that it can also binds to STAT1 [23].
We therefore sought to examine whether the STAT3 decoy
oligonucleotide inhibited STAT1 in endothelial cells. HUVECs
treated with the STAT3 decoy oligonucleotide or mutant control
decoy were stimulated with interferon gamma (IFN-c), and
Western blot was then performed for interferon response factor
1 (IRF-1). Induction of IRF-1 expression by IFN-c is primarily a
STAT1 mediated process, and serves as an indicator of the
integrity of the STAT1 pathway [24]. We observed that treatment
of HUVEC with STAT3 decoy oligonucleotide inhibited the IFN-
c induced IRF-1 (Fig. 4A & B). This data suggested that in
HUVEC, STAT3 decoy oligonucleotide binds to not only STAT3
but STAT1 as well.
To examine whether the effects of STAT3 oligonucleotide on
tubule formation was due to the inhibition of STAT3, STAT1 or
both, we then examined the effects of the downregulation of
STAT1 alone, STAT3 alone, or both STAT1 and STAT3 on
HUVEC proliferation and tubule formation. The down regulation
of STAT1 alone or STAT3 alone did not result in statistically
significant decrease in tubule formation compared with the control
siRNA. However, only the combined downregulation of STAT1
and STAT3 resulted in statistically significantdecrease in tubule
formation compared with the control siRNA (Fig. 4C–F). These
results suggest that both STAT1 and STAT3 are involved in the
process of in vitro tubule formation and that the decrease in tubule
formation seen with STAT3 decoy oligonucleotide is produced by
the dual inhibition of STAT1 and STAT3.
Treatment of tumor xenografts with STAT3 decoy
oligonucleotide decreases microvessel density in vivo
While the HUVECs are one of the most frequently utilized cell-
model for studying angiogenesis in vitro, tubule formation assays do
not replicate the complex process of in vivo tumor angiogenesis. In
order to confirm our in vitro findings, we examined the in vivo ability
Figure 1. Effects of STAT3 decoy oligonucleotide on the proliferation, apoptosis, and migration of HUVECs and HDMECsin vitro. (A)
HUVECs and (B) HDMECs were transfected with the STAT3 decoy oligonucleotide or mutant control oligonucleotide at 0 nM to 1000 nM. Seventy two
hours later the cells were assessed for proliferation using MTT assay. Results are shown in percent kill relative to the mutant control oligonucleotide
and the experiments were performed in triplicate. (C) HUVECs were transfected with the either STAT3 decoy oligonucleotide (0 nM to 100 nM), the
mutant control oligonucleotide (100 nM), vehicle, or cisplatin (100 mM). Twenty four hours later the cells were analyzed for apoptosis using Annexin V
staining and flow cytometry. The experiments were performed in triplicate (* p,0.05). (D) HUVECs were transfected with 100 nM of STAT3 decoy
oligonucleotide or 100 nM of STAT3 of mutant control oligonucleotide, plated inTranswell8uM pore inserts, and extent of migration was ascertained
24 hrs later. STAT3 decoy oligonucleotide decreased the migration of HUVEC compared with the mutant control oligonucleotide (* p,0.05). All of
the experiments were performed in triplicate.
doi:10.1371/journal.pone.0081819.g001
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of STAT3 decoy oligonucleotide to inhibit tumor angiogenesis.
For this study, HNSCC cell line UM-22 was used to produce
xenografts in nude mice. Once palpable tumors were present, the
mice were treated daily with intratumoral injection of vehicle
(saline), mutant control oligonucleotide, or the STAT3 decoy
oligonucleotide. The tumors were then examined with both CD31
immunohistochemistry and dual CD31/TUNEL immunofluores-
cence (Fig. 5A & B). Compared with the mutant control
oligonucleotide treated or saline treated tumors, STAT3 decoy
oligonucleotide treated tumors showed a statistically significant
decrease in microvessel density (p,0.05) (Fig. 5a and 5b).
Additionally, dual CD31/TUNEL staining showed an increase
in the endothelial cell apoptosis in the STAT3 decoy oligonucle-
otide group compared to the mutant control oligonucleotide or
saline treated group (p,0.05) (Fig. 5C & D).
STAT3 decoy oligonucleotide directly inhibits
angiogenesis
It has been well documented that VEGF is a STAT3 target
gene and that the inhibition of STAT3 results in decreased
production of VEGF [25–27]. We next sought to examine whether
the decrease in the microvessel density (seen in the previous
experiment) was due to a direct effect of the STAT3 decoy
oligonucleotide on the endothelial cell or a result of a decrease in
tumor cell production of VEGF. We utilized, for this purpose, a
murine model of in vivo angiogenesis that is not dependent on the
presence of any tumor cells. In this assay, HUVECs and Matrigel
(1:1) were seeded onto poly-L-lactic acid (PLLA) sponges and then
the sponges were implanted into subcutaneous tissue of nude mice
[20,21]. The mice were then treated via peri-scaffold injection of
50 mg of either the STAT3 decoy oligonucleotide or the mutant
control oligonucleotide. The sponges were removed after two
weeks of treatment and immunofluorescent staining was per-
formed against human CD31. Treatment of the PLLA sponges
with STAT3 decoy oligonucleotide resulted in a statistically
significant decrease in the formation of blood vessels within the
sponges compared with PLLA sponges treated with STAT3
mutant decoy oligonucleotide (p,0.05) (Fig. 6A–C). These results
suggested that the decreases in microvessel density seen in tumor
xenograft were in part due to direct effect of the STAT3 decoy
oligonucleotide on tumor endothelium.
Discussion
STAT3 has been proposed as a therapeutic target for tumor
cells as it is a downstream mediator of EGFR and IL6, both of
which have been shown to be important in carcinogenesis and
angiogenesis [28]. There are small molecule tyrosine kinase
inhibitors that have been designed to inhibit the janus kinase 2
(JAK2)-STAT3 pathway including AG490 and AZD1480, and
several of these agents are being studied in clinical trial setting
[29,30]. We have been interested in the use of decoy oligonucle-
otide as a therapeutic approach for inhibiting STAT3. Our
institution has recently initiated and completed a biomarker-
driven neoadjuvant phase 0 clinical trial of the STAT3 decoy in
patients with resectable head and neck cancer. In fact, the STAT3
decoy oligonucleotide is the only STAT3 inhibitor that has
progressed to clinical evaluation in patients with cancer of thehead
and neck [11]. Despite the progress of the STAT3 decoy as a
therapeutic agent in head and neck cancer, little work has been
done to understand how this agent affects other aspects of
tumorigenesis such as angiogenesis. Additionally, there has never
been an agent designed to inhibit angiogenesis by targeting
nuclear transcription factors.
We have demonstrated in this study that the STAT3 decoy
oligonucleotide has significant antiangiogenic properties. We have
found that STAT3 decoy oligonucleotide decreased the viability
and induced apoptosis of HUVECs and HDMECs in vitro. It
should be noted that STAT3 decoy oligonucleotide does not have
cytotoxic effects on normal tissues such as normal oral keratino-
cytes in the range used in our study [9].
The role of STAT1 and STAT3 in the process of angiogenesis
has been examined in several previous publications. It has been
shown in several studies that STAT3 is downstream from
VEGFR2 and is activated by the binding of VEGF to VEGFR2
[15,16,31]. Schaefer et al has found that STAT3 is constitutively
activated in tumor endothelium of glioma and medulloblastoma
tumors suggesting that STAT3 is involved in tumor angiogenesis
[32]. On the other hand, several studies have suggested that
STAT1 is a negative regulator of angiogenesis. A study by Battle et
al showed that the activation of STAT1 by IFN-c lead to
decreased tubule formation by HUVEC in vitro. This study further
found decreased microvessel density in STAT1-/- mice with
Matrigel plug assay compared with wild-type control mice [33].
The role of STAT1 in tumor angiogenesis was assessed in a study
by Huang et al using a highly angiogenic murine fibrosarcoma cell
line derived from STAT1 -/- mice. When STAT1 expression was
restored using a STAT1 expression vector, the cell line showed
decreased growth in vivo as well as decreased microvessel density
[34]. Our data suggest that the inhibitory effect of STAT3 decoy
oligonucleotide on angiogenesis may be due to the inhibition of
both STAT1 and STAT3. One possible explanation for this effect
Figure 2. STAT3 decoy inhibits HUVEC tubule formation. (A)
HUVECs were transfected with 100 nM of STAT3 decoy oligonucleotide
or 100 nM of STAT3 mutant control oligonucleotide. Twenty four hours
later 15,000 cells were plated on top of Matrigel in a 96-well plate. After
24 additional hours the plates were assessed for tubule formation. The
tubule formation was the quantified by counting the total number of
(B) nodes and (C) tubules per field. Stat3 decoy oligonucleotide
decreased both node and tubule number compared to the STAT3
mutant (*, ** p,0.05). All of the experiments were performed in
triplicates.
doi:10.1371/journal.pone.0081819.g002
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Figure 3. STAT3 decoy inhibits net migration of HUVECs during in vitro tubule formation. HUVECs were transfected with 100 nM of the
STAT3 decoy oligonucleotide or mutant control oligonucleotide. Twenty four hours later, the cells were plated on Matrigel coated culture dishes.
Images were captured at 206every ten minutes for the following 24 hours in eight different fields. (A) The decoy was FAM-tagged (green) in order to
ensure positive transfection. (B) Representative images from various time points from the course of the experiment.The live cell images were
quantified for three distinct parameters: (C) mean distance traveled,(D) mean velocity, and (E) distance from origin. The distance from origin was
significantly decreasedby STAT3 decoy oligonucleotide compared to the STAT3 mutant oligonucleotide (** p,0.05). All of the experiments were
performed in triplicates.
doi:10.1371/journal.pone.0081819.g003
Antiangiogenic STAT3 Decoy Oligonucleotide
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is that the STAT1/STAT3 heterodimers have a distinct role in
tumor angiogenesis independent from the role of STAT1 or
STAT3 homodimers, but further work is necessary to elucidate
this effect.
While we are convinced that the anti-angiogenic effect we
observe with the STAT3 decoy is not solely due to its inhibition of
STAT3, the agent is nonetheless effective at inhibiting tubule
formation in vitro and in decreasing tumor angiogenesis in vivo. The
Figure 4. STAT3 decoy has additionally activity against STAT1. (A) HUVECs were transfected with 100 nM of STAT3 decoy oligonucleotide.
Twenty four hour after transfection, the cells were stimulated with IFN-c (20 ng/ml for one hr) and Western blot was performed for IRF-1. (B)
Densitometric measurement of IRF-1 (** P,0.05). (C) HUVECs were transfected with either STAT1 siRNA, STAT3 siRNA or both. Western blot was then
performed to confirm the downregulation of STAT1, STAT3, or both. (D) Downregulation of STAT1 or STAT3 did not result in decreased tubule
formation. In contrast, combined downregulation of both STAT1 and STAT3 resulted in statistically significant decrease in tubule formation.
Quantification of tubule formation by (E) total number of nodes per field and (F) total number of tubules per field (* p,0.05).
doi:10.1371/journal.pone.0081819.g004
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goal of this study was to identify a compound that can effectively
target both the tumor cell and endothelial cell compartment of a
tumor. Other such therapeutic approaches include strategies such
as combining Bevacizumab with EGFR TKIs such as Erlotinib
[35]. However, one limitation of a dual agent approach is the
increase in adverse effects with the use of multiple agents as well as
possible unwarranted interaction that can occur between the two
agents.
Single agent approach to dual tumor cell and endothelial cell
compartment targeting has been explored with agents such as
Vandatenib (ZD6474). However, recent clinical trials of Vande-
tanib in lung cancer has been disappointing [36]. Additionally,
TKIs with dual specificity usually have target profile that
preferentially inhibits one of their targets (ZD6474 is more than
ten times selective for VEGFR2 than EGFR) and also have non-
specific off target effects. The STAT3 decoy oligonucleotide has
greater specificity as it is an oligonucleotide, and we have shown
previously that it has very low toxicity profile in primates [12].
Taken together with the previously demonstrated antitumor
activity of this agent as well as anti-angiogenic effects demonstrat-
ed in this study, we believe that the STAT3 decoy oligonucleotide
represents a promising single agent approach to targeting both the
tumor and vascular compartments in various malignancies. Lastly,
the elucidation of antiangiogenic properties of STAT3 decoy
oligonucleotide elucidated in this study will aid in the identification
of relevant biomarkers in clinical trials of STAT3 inhibitors and
should allow for proper patient selection for these trials.
Figure 5. STAT3 decoy treatment of tumor xenografts decreases microvessel density and increases endothelial cell apoptosis.
HNSCC xenografts were produced in nude mice using the cell line UM-22B. The mice were then treated with direct intratumoral injection with
vehicle, STAT3 decoy, or mutant control oligonucleotide for 3 weeks. The tumors were then analyzed with immunohistochemical staining for CD31
for microvessel density or dual staining for CD31/TUNEL for endothelial cell apoptosis. Representative images of (A) CD31 stainingand (B) dual CD31/
TUNEL staining, where red is CD31 and green is TUNEL. (C) Quantification of microvessel density (** p,0.001). (D) Quantification endothelial cell
apoptosis density (** p,0.001).
doi:10.1371/journal.pone.0081819.g005
Antiangiogenic STAT3 Decoy Oligonucleotide
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